Successful Imatinib Therapy for Neuroendocrine Carcinoma With Activating KIT Mutation: A Case Study
Search for other papers by James Perkins in
Current site
Google Scholar
PubMed
Search for other papers by Patrick Boland in
Current site
Google Scholar
PubMed
Search for other papers by Steven J. Cohen in
Current site
Google Scholar
PubMed
Search for other papers by Anthony J. Olszanski in
Current site
Google Scholar
PubMed
Search for other papers by Yan Zhou in
Current site
Google Scholar
PubMed
Search for other papers by Paul Engstrom in
Current site
Google Scholar
PubMed
From the Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Department of Medicine, Division of Medical Oncology, Roswell Park Cancer Institute, Buffalo, New York; Biostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and Department of Biochemistry, Kazan Federal University, Russia.
Search for other papers by Igor Astsaturov in
Current site
Google Scholar
PubMed
Neuroendocrine tumors (NET) and gastrointestinal stromal tumors (GIST) are believed to originate from the cells of Cajal that are randomly dispersed along the aerodigestive tract. Despite their distinct morphologic appearance, NET and GIST may share oncogenic mechanisms. Often presenting in the metastatic setting, treatment options for patients with NET are limited. This case report presents a patient with refractory metastatic NET that did not respond conventional chemotherapy. The patient was treated with a KIF11 inhibitor in a phase I clinical trial and experienced a prolonged and clinically meaningful partial response. On progression at 20 months, the patient’s tumor was sequenced to reveal a KIT exon 11 mutation. Institution of imatinib therapy achieved a rapid and sustained antitumor effect with profound clinical benefit. Despite previously reported KIT expression in NET, this is the first documented case of an activating KIT mutation in NET and of successful treatment with both a KIF11 inhibitor and imatinib, each of which was elucidated through molecular profiling of the patient’s tumor. Imatinib may be a valuable therapy in NET harboring activating KIT mutations.
Supplementary Materials
- Supplemental Material (PDF 274 KB)
© 2019-2024 National Comprehensive Cancer Network